Skip to main content

Ikarian Capital, LLC

Position in KALV — KalVista Pharmaceuticals, Inc.

CIK 1778253 DALLAS, TX

Position in KALV

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$706,945
+$139,774 QoQ
Shares Held
35,119
0.0% QoQ
Ownership
0.066%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#87
of 182 holders
Holding Since
Mar 2020
16 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in KALV Over Time

Shares Held

Position Value (USD)

Derivatives in KALV

reported options exposure · as of Sep 30, 2025
CallValue
$4,872,000
CallShares
400,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Ikarian Capital, LLC holds $659,799,686 across 106 Biotechnology names. KALV ranks #75 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in KALV

Export CSV
18 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $706,945 35,119
2025-12-31 $567,171 35,119
2025-09-30 $4,872,000 400,000
2025-06-30 $4,522,000 400,000
2025-06-30 $2,244,359 198,528
2023-09-30 $1,374,123 142,692
2023-06-30 $1,260,000 140,000
2023-03-31 $1,100,400 140,000
2022-03-31 $585,620 39,730
2021-12-31 $483,900 36,576
2021-09-30 $1,685,251 96,576
2021-06-30 $2,323,281 96,965
2021-03-31 $7,629,030 296,965
2020-12-31 $20,204,619 1,063,961
2020-12-31 $2,763,045 145,500
2020-09-30 $15,554,579 1,235,471
2020-06-30 $13,472,079 1,113,395
2020-03-31 $7,241,528 946,605